日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

HER2 Protein Overexpression, mRNA Expression, and DNA Amplification Across Solid Tumors: Comparison of Next-Generation Sequencing-Based Assays With Immunohistochemistry

HER2蛋白过表达、mRNA表达和DNA扩增在实体瘤中的分布:基于新一代测序的检测方法与免疫组织化学的比较

Nagamine, Michiko; Fujisawa, Takao; Sakamoto, Naoya; Nakamura, Yoshiaki; Kadowaki, Shigenori; Ueno, Makoto; Boku, Shogen; Komatsu, Yoshito; Oki, Eiji; Makiyama, Akitaka; Nonomura, Norio; Morizane, Chigusa; Watari, Hidemichi; Okano, Susumu; Iwata, Hiroji; Namikawa, Kenjiro; Hatanaka, Yutaka; Hatanaka, Kanako C; Taguchi, Kenichi; Spetzler, David; Radovich, Milan; Magee, Daniel; Yoshino, Takayuki; Oberley, Matthew; Kuwata, Takeshi

Clinicomolecular Profile and Efficacy of Human Epidermal Growth Factor Receptor 2 (HER2)-Targeted Therapy for HER2-Amplified Advanced Biliary Tract Cancer

HER2扩增型晚期胆道癌的临床分子特征及人表皮生长因子受体2 (HER2)靶向治疗疗效

Inoue, Kanae; Nakamura, Yoshiaki; Caughey, Bennett; Zheng-Lin, Binbin; Ueno, Makoto; Furukawa, Masayuki; Kawamoto, Yasuyuki; Itoh, Shinji; Umemoto, Kumiko; Sudo, Kentaro; Satoh, Taroh; Mizuno, Nobumasa; Kajiwara, Takeshi; Fujisawa, Takao; Bando, Hideaki; Yoshino, Takayuki; Strickler, John H; Morizane, Chigusa; Bekaii-Saab, Tanios; Ikeda, Masafumi

Efficacy of liposomal irinotecan + 5-FU/LV vs. S-1 in gemcitabine-refractory metastatic pancreatic cancer: a real-world study using inverse probability of treatment weighting

脂质体伊立替康+5-FU/LV与S-1治疗吉西他滨难治性转移性胰腺癌的疗效比较:一项采用逆概率加权法的真实世界研究

Imaoka, Hiroshi; Ikeda, Masafumi; Kobayashi, Satoshi; Ohba, Akihiro; Ueno, Masayuki; Suzuki, Yuko; Tsumura, Hidetaka; Kimura, Nana; Kawaguchi, Shinya; Kawamoto, Yasuyuki; Nakachi, Kohei; Tsuji, Kunihiro; Kobayashi, Noritoshi; Ashida, Reiko; Okano, Naohiro; Umemoto, Kumiko; Murohisa, Gou; Hosokawa, Ayumu; Asagi, Akinori; Nebiki, Hiroko; Suzuki, Rei; Terashima, Takeshi; Shibata, Ryusuke; Kawata, Kazuhito; Doi, Toshifumi; Ohyama, Hiroshi; Kitano, Yohei; Shioji, Kazuhiko; Okuyama, Hiroyuki; Naganuma, Atsushi; Negoro, Yuji; Sakamoto, Yasunari; Shimizu, Satoshi; Morizane, Chigusa; Ueno, Makoto; Furuse, Junji; Nagano, Hiroaki

Correction: Efficacy of liposomal irinotecan + 5-FU/LV vs. S-1 in gemcitabine-refractory metastatic pancreatic cancer: a real-world study using inverse probability of treatment weighting

更正:脂质体伊立替康+5-FU/LV与S-1治疗吉西他滨难治性转移性胰腺癌的疗效比较:一项采用逆概率加权法的真实世界研究

Imaoka, Hiroshi; Ikeda, Masafumi; Kobayashi, Satoshi; Ohba, Akihiro; Ueno, Masayuki; Suzuki, Yuko; Tsumura, Hidetaka; Kimura, Nana; Kawaguchi, Shinya; Kawamoto, Yasuyuki; Nakachi, Kohei; Tsuji, Kunihiro; Kobayashi, Noritoshi; Ashida, Reiko; Okano, Naohiro; Umemoto, Kumiko; Murohisa, Gou; Hosokawa, Ayumu; Asagi, Akinori; Nebiki, Hiroko; Suzuki, Rei; Terashima, Takeshi; Shibata, Ryusuke; Kawata, Kazuhito; Doi, Toshifumi; Ohyama, Hiroshi; Kitano, Yohei; Shioji, Kazuhiko; Okuyama, Hiroyuki; Naganuma, Atsushi; Negoro, Yuji; Sakamoto, Yasunari; Shimizu, Satoshi; Morizane, Chigusa; Ueno, Makoto; Furuse, Junji; Nagano, Hiroaki

First Successful Treatment of Advanced Intrahepatic Cholangiocarcinoma with Tasurgratinib Following Regulatory Approval: A Case Report from Clinical Practice

Tasurgratinib获批后首次成功治疗晚期肝内胆管癌:临床实践病例报告

Maruki, Yuta; Morizane, Chigusa; Okada, Mao; Harai, Shota; Nagashio, Yoshikuni; Hijioka, Susumu; Ueno, Hideki; Okusaka, Takuji

Metal stent versus plastic stent in endoscopic ultrasound-guided hepaticogastrostomy for unresectable malignant biliary obstruction: Large single-center retrospective comparative study

内镜超声引导下肝胃吻合术治疗不可切除的恶性胆道梗阻:金属支架与塑料支架的比较:一项大型单中心回顾性比较研究

Yamashige, Daiki; Hijioka, Susumu; Nagashio, Yoshikuni; Maruki, Yuta; Komori, Yasuhiro; Kuwada, Masaru; Fukuda, Soma; Yagi, Shin; Okamoto, Kohei; Agarie, Daiki; Chatto, Mark; Morizane, Chigusa; Ueno, Hideki; Sugawara, Shunsuke; Sone, Miyuki; Saito, Yutaka; Okusaka, Takuji

Clinical significance and efficacy of endoscopic ultrasound-guided tissue acquisition for para-aortic lymph node metastasis

内镜超声引导下组织获取在主动脉旁淋巴结转移中的临床意义和疗效

Hara, Hidenobu; Hijioka, Susumu; Yamashige, Daiki; Nagashio, Yoshikuni; Komori, Yasuhiro; Kuwada, Masaru; Fukuda, Soma; Yagi, Shin; Okamoto, Kohei; Agarie, Daiki; Chatto, Mark; Okada, Mao; Maruki, Yuta; Morizane, Chigusa; Ueno, Hideki; Saito, Yutaka; Yonemori, Kan; Okusaka, Takuji

Tasurgratinib in patients with cholangiocarcinoma or gastric cancer: Expansion part of the first-in-human phase I study

Tasurgratinib治疗胆管癌或胃癌患者:首次人体I期研究的扩展部分

Morizane, Chigusa; Ueno, Makoto; Ioka, Tatsuya; Tajika, Masahiro; Ikeda, Masafumi; Yamaguchi, Kensei; Hara, Hiroki; Yabusaki, Hiroshi; Miyamoto, Atsushi; Iwasa, Satoru; Muto, Manabu; Takashima, Tsutomu; Minashi, Keiko; Komatsu, Yoshito; Nishina, Tomohiro; Nakajima, Takako Eguchi; Takeno, Atsuchi; Moriwaki, Toshikazu; Furukawa, Masayuki; Sahara, Takatoshi; Ikezawa, Hiroki; Nomoto, Maiko; Takashima, Shuya; Uehara, Taisuke; Funasaka, Setsuo; Yashiro, Masakazu; Furuse, Junji

Landscape Analysis of CLDN18 Expression and Isoform Distribution in Solid Tumors: Insights From MONSTAR-SCREEN-2 Study.

实体瘤中 CLDN18 表达和亚型分布的景观分析:来自 MONSTAR-SCREEN-2 研究的启示

Hashimoto Tadayoshi, Iida Naoko, Nakamura Yoshiaki, Nonomura Norio, Morizane Chigusa, Iwata Hiroji, Okano Susumu, Yamagami Wataru, Yamazaki Naoya, Kadowaki Shigenori, Ueno Makoto, Boku Shogen, Oki Eiji, Komatsu Yoshito, Yuki Satoshi, Makiyama Akitaka, Ogata Takatsugu, Takahashi Naoki, Okano Naohiro, Nishina Tomohiro, Sakamoto Naoya, Kuwata Takeshi, Yamashita Riu, Shibuki Taro, Imai Mitsuho, Fujisawa Takao, Bando Hideaki, Shitara Kohei, Yoshino Takayuki

Incidence and site specific characteristics of angiosarcoma in Japan using a population-based national cancer registry from 2016 to 2019

利用2016年至2019年日本基于人群的国家癌症登记数据,分析血管肉瘤在日本的发病率和部位特异性特征

Takemori, Toshiyuki; Ogura, Koichi; Morizane, Chigusa; Satake, Tomoyuki; Iwata, Shintaro; Toda, Yu; Muramatsu, Shudai; Kondo, Hiroya; Kobayashi, Eisuke; Higashi, Takahiro; Kawai, Akira